A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.
European journal of cancer (Oxford, England : 1990)（2022）
摘要
gov identifier: NCT01141491.
更多查看译文
关键词
Adjuvant,Ganglioside,Sarcoma,Vaccine
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要